The Top 5 Biosimilar Articles for the Week of July 5

Video

Here are the top 5 biosimilar articles for the week of July 5, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of July 5, 2021.

Number 5: Teva and Bioeq partnered on a ranibizumab biosimilar, Organon joined the Biosimilars Forum, and the Alliance for Patient Access issued educational material for oncology biosimilars.

Number 4: Hoping to stimulate greater use of biosimilars, 28 patient advocacy groups threw their weight behind draft legislation that would increase Medicare reimbursement to health care institutions when they prescribe biosimilars to patients.

Number 3: Early study results indicated that STADA Arzneimittel and Xbrane Biopharma’s ranibizumab biosimilar is as safe and effective as the reference product, suggesting regulatory approval may be on the horizon.

Number 2: Insulin aspart, lispro, and glargine biosimilar candidates referencing NovoRapid, Humalog, and Lantus demonstrated bioequivalence in trial data presented at the Scientific Sessions of the American Diabetes Association.

Number 1: Our roundup for June 2021 detailed some of the biggest news to come out of the biosimilar industry this month, ranging from poignant business updates to reactions from key opinion leaders on regulatory decisions from around the world.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Here are the top 5 biosimilar articles for the week of November 27, 2023.
Chelsee Jensen, PharmD, BCPS
Here are the top 5 biosimilar articles for the week of November 20, 2023.
Here are the top 5 biosimilar articles for the week of November 13, 2023.
GBW 2023 webinar
Ryan Haumschild, PharmD, MS, MBA
Related Content
© 2023 MJH Life Sciences

All rights reserved.